Skip to main content
Premium Trial:

Request an Annual Quote

Fulgent Genetics Wins VA Testing Contract Worth up to $99M

NEW YORK – Fulgent Genetics said Thursday that it has been awarded a five-year contract by the US Department of Veterans Affairs to provide hereditary cancer, pharmacogenetic, and other genetic testing to veterans. The award provides for up to $99 million over five years.

Fulgent has been providing both clinical and research-use genetic testing services for the VA since 2017. The new contract covers the provisions of hereditary cancer testing for individuals with cancer or a family history of certain cancers, as well as pharmacogenetic testing intended to determine how patients will respond to certain medications.

"We are excited to leverage our flexible testing options to serve the VA community and provide VA physicians the tools to practice genomic medicine," Fulgent CSO Harry Gao said in a statement.